Switch to Budesonide Tablets Improve Remission in EoE
TOPLINEPatients with eosinophilic esophagitis (EoE) who switched from budesonide viscous solution (BVS) to budesonide orodispersible tablets (BOT) at the same dose and schedule experienced significant improvements in histological and deep histological remission rates. Endoscopic scores also improved significantly, and health-related quality of life (HRQOL) increased, though a numeric rise in endoscopic suspicion of candidiasis was observed. IN PRACTICE"BOT may be a potential rescue option in patients who fail BVS therapy, prior to escalation of (biological) treatment strategies," wrote the authors of the study.SOURCEThe study was led by Jana Defrancq, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
- ▪TOPLINEPatients with eosinophilic esophagitis (EoE) who switched from budesonide viscous solution (BVS) to budesonide orodispersible tablets (BOT) at the same dose and schedule experienced significant improvements in histological and deep h
- ▪Endoscopic scores also improved significantly, and health-related quality of life (HRQOL) increased, though a numeric rise in endoscopic suspicion of candidiasis was observed.
- ▪IN PRACTICE"BOT may be a potential rescue option in patients who fail BVS therapy, prior to escalation of (biological) treatment strategies," wrote the authors of the study.SOURCEThe study was led by Jana Defrancq, Department of Chronic Dis
Medscape files mainly under health. We currently carry 231 of its stories.
Opening excerpt (first ~120 words) tap to expand
TOPLINEPatients with eosinophilic esophagitis (EoE) who switched from budesonide viscous solution (BVS) to budesonide orodispersible tablets (BOT) at the same dose and schedule experienced significant improvements in histological and deep histological remission rates. Endoscopic scores also improved significantly, and health-related quality of life (HRQOL) increased, though a numeric rise in endoscopic suspicion of candidiasis was observed. METHODOLOGYResearchers conducted a retrospective analysis of a prospectively collected dataset including 45 adult patients with EoE who switched from BVS to BOT at the same dose (1 mg) and dosing schedule (32 patients switched in a once-daily [OD] schedule; 13 in a twice-daily schedule) at University Hospitals Leuven, Belgium.Patients had been on BVS…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape Medical News Headlines.
Discussion
0 commentsMore from Medscape Medical News Headlines
